Tango Therapeutics reports 82% response rate and 88% nine‑month PFS in pancreatic cancer trial, plans 2027 Phase 3
Tango Therapeutics announced that its Phase 1/2 study of the PRMT5 inhibitor vopimetostat combined with the RAS(ON) inhibitor daraxonrasib achieved an 82% objective response rate in 22 efficacy‑evaluable pancreatic cancer patients and an 88% progression‑free survival rate at nine months. The data, presented at the ESMO 2026 Congress, were derived from patients treated in second‑ or third‑line settings and were reported as generally well‑tolerated. The company said it will launch a global, randomized registrational Phase 3 trial in front‑line MTAP‑deleted pancreatic cancer in the first half of 2027.
Why it matters
The strong efficacy signals could position the combination as a potential new standard of care, but the stock fell 6% on the news, indicating market skepticism or profit‑taking. The upcoming Phase 3 trial will determine whether the early results translate into regulatory approval and commercial revenue.
Key facts
- 1The Phase 1/2 study showed an 82% objective response rate in 22 efficacy‑evaluable pancreatic cancer patients. stocktitan.net
- 2Nine‑month progression‑free survival was 88% in the same patient cohort. stocktitan.net
- 3Median follow‑up for the 22 patients was 7.1 months (range 3.3‑12.5 months). stocktitan.net
- 4The data cutoff date for the results was August 20, 2026. stocktitan.net
- 5Tango plans to initiate a global, randomized registrational Phase 3 trial of vopimetostat plus daraxonrasib in front‑line MTAP‑deleted pancreatic cancer in the first half of 2027. stocktitan.net
- 6Tango Therapeutics' shares fell 6% after the announcement. investing.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.